dc.contributor
Institut Català de la Salut
dc.contributor
[de Stefano N] Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. [Barkhof F] Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands. UCL Institute of Neurology, London, UK. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Achiron A] Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel. [Derfuss T] Department of Neurology, University Hospital Basel, Basel, Switzerland. [Chan A] Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Montalban Gairín, Xavier
dc.contributor.author
Achiron, Anat
dc.contributor.author
Chan, Andrew
dc.contributor.author
Barkhof, Frederik
dc.contributor.author
De Stefano, Nicola
dc.contributor.author
Derfuss, Tobias
dc.date.accessioned
2025-10-24T10:34:05Z
dc.date.available
2025-10-24T10:34:05Z
dc.date.issued
2022-09-12T08:25:22Z
dc.date.issued
2022-09-12T08:25:22Z
dc.identifier
de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, et al. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022 Jul;9(4):e1187.
dc.identifier
https://hdl.handle.net/11351/8138
dc.identifier
10.1212/NXI.0000000000001187
dc.identifier
000816701200018
dc.identifier.uri
http://hdl.handle.net/11351/8138
dc.description.abstract
Active Relapsing Multiple Sclerosis; MRI; Cladribine
dc.description.abstract
Esclerosis Múltiple Recurrente Activa; Imagen por resonancia magnética; Cladribina
dc.description.abstract
Esclerosi múltiple recurrent activa; Imatge per ressonància magnètica; Cladribina
dc.description.abstract
Background and Objectives The onset of action for high-efficacy immunotherapies in multiple sclerosis (MS) is an important parameter. This study (MAGNIFY-MS) evaluates the onset of action of cladribine tablets by observing changes in combined unique active (CUA) MRI lesion counts during the first 6 months of treatment in patients with highly active relapsing MS.
Methods MRI was performed at screening, baseline, and at months 1, 2, 3, and 6 after initiating treatment with cladribine tablets 3.5 mg/kg. CUA lesion counts, defined as the sum of T1 gadolinium-enhancing (Gd+) lesions and new or enlarging active T2 lesions (without T1 Gd+), were compared between postbaseline and the baseline period and standardized to the period length and the number of MRIs performed.
Results Included in this analysis were 270 patients who received ≥1 dose of cladribine tablets. After treatment initiation, significant reductions in mean CUA lesion counts were observed from month 1 onward compared with the baseline period (−1.193 between month 1 and month 6, −1.500 between month 2 and month 6, and −1.692 between month 3 and month 6; all p < 0.0001). Mean T1 Gd+ lesion counts were decreased from month 2 onward compared with baseline (−0.857 at month 2, −1.355 at month 3, and −1.449 at month 6; all p < 0.0001), whereas the proportion of patients without any CUA lesions increased from 52.0% between month 1 and month 6 to 80.5% between month 3 and month 6.
Discussion Findings suggest an early onset of action for cladribine tablets, with an increasing reduction in active MRI lesions over time.
Trial Registration Information NCT03364036; Date registered: December 06, 2017.
dc.description.abstract
This study was supported by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).
dc.format
application/pdf
dc.publisher
Lippincott Williams & Wilkins
dc.relation
Neurology - Neuroimmunology & Neuroinflammation;9(4)
dc.relation
https://doi.org/10.1212/NXI.0000000000001187
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple - Imatgeria per ressonància magnètica
dc.subject
Comprimits (Medicina) - Ús terapèutic
dc.subject
DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
dc.title
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
